Related Experiment Video
Updated: Nov 15, 2025

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
Abstract:
Enfortumab vedotin recently demonstrated greater efficacy than standard chemotherapy in patients with previously treated advanced urothelial cancer: In a phase III trial, the agent led to a median overall survival of 12.9 months, compared with 9 months in patients who received chemotherapy.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
06:01Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
Published on: October 6, 2022
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers